Momcozy Survey Finds Moms Face Biggest Challenges of Time and Breast Pump Management, When Referring to Breastfeeding and Pumping Demands
23.2.2023 09:07:00 EET | Business Wire | Press release
In a recent survey, Momcozy, the best-selling wearable breast pump brand in North America found that moms struggle with breastfeeding and breast pumping mostly due to a lack of time, space, and the right breast pump. In addition, wearable breast pumps that allow moms to pump hands-free anywhere to balance life enjoyment and nursing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230222005522/en/
Momcozy Breastfeeding and Pumping Experience Survey results (Graphic: Business Wire)
The survey was conducted from July 25th, 2022- September 13th, 2022, via Momcozy’s social media accounts and newsletter targeting North American moms, and garnered nearly 1000 responses, which found:
- Moms face many hurdles to successful breastfeeding, including breast health issues, latching problems, and isolation sense. The most common difficulty however was managing the time to pump around busy schedules, along with the difficulties of breast pump management.
- Generally, moms with wireless, wearable pumps reported more positive pumping experiences compared with their traditional breast pump counterparts.
- Most respondents pump at home, at work, or in transit, indicating moms spend most of their time between taking care of their child, and earning income.
- In terms of the ‘craziest’ place moms ever breast pumped, the most mentioned locations included at meetings, the grocery store, parties, and restaurants. Other locations mentioned such as festivals, amusement parks and sports games indicate that for some moms, wearable breast pumps allow them greater flexibility and freedom to do things they like.
These findings suggest that every minute of breastfeeding and expressing moms counts. While expressing goals can still be difficult, wearable breast pumps allow moms to express comfortably anytime, anywhere with confidence and freedom. In short, mothers have little time to choose when and where to express for themselves. But with a hands-free, wearable breast pump, moms can feel more secure pumping anywhere without missing out on the fun of their lives.
The Momcozy S12 Pro Wearable Breast Pump was developed with the full understanding of mothers' feeding needs. It can be seamlessly integrated into the busy schedule of mothers, providing an efficient breastfeeding experience and long battery life support to meet the needs of breastfeeding in various scenarios.“Always put moms on top” is what Momcozy has been fulfilling. Through cozy designs born from love and continuous innovation, Momcozy brings a much simpler, more relaxed, and more comfortable experience for moms globally through their pregnancy and early motherhood.
About Momcozy
Momcozy, the renowned maternity and baby brand endorsed by over 2 million moms, is the best companion for moms globally through their pregnancy and early motherhood. Centering around wearable breast pumps, Momcozy offers a wide range of products covering nursing, clothing and textile, FMCG, security, and more to accompany moms through their pregnancy and early motherhood in a more comfy and convenient way, making it the choice of Gen Z and millennial moms.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005522/en/
Contact information
Marketing Dept.
Ella Zheng
1-855-322-1777(Mon.-Fri. 8:30am-12:00pm;1:00pm-5:30pm PST)
ella.zheng@momcozy.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
